TD Cowen Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $306.00

Krystal Biotech (NASDAQ:KRYS) had its target price hoisted by analysts at TD Cowen from $202.00 to $306.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s target price would indicate a potential upside of 17.06% from the company’s current price.

Several other equities research analysts have also recently commented on KRYS. Zacks Research raised Krystal Biotech from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Guggenheim set a $224.00 price target on Krystal Biotech and gave the company a “buy” rating in a research report on Friday, October 17th. Cowen restated a “buy” rating on shares of Krystal Biotech in a report on Friday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Finally, Citigroup upgraded shares of Krystal Biotech from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $198.00 to $309.00 in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $260.50.

Krystal Biotech Stock Up 5.0%

KRYS stock opened at $261.41 on Friday. The company has a market capitalization of $7.58 billion, a P/E ratio of 39.19 and a beta of 0.46. The company has a 50-day simple moving average of $227.55 and a 200 day simple moving average of $182.63. Krystal Biotech has a fifty-two week low of $122.80 and a fifty-two week high of $267.48.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating the consensus estimate of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million for the quarter, compared to analysts’ expectations of $93.72 million. Equities analysts anticipate that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the completion of the transaction, the insider owned 1,413,711 shares in the company, valued at $311,242,613.76. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Hantz Financial Services Inc. boosted its holdings in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after buying an additional 179 shares during the period. Bessemer Group Inc. lifted its position in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after acquiring an additional 77 shares in the last quarter. AdvisorNet Financial Inc acquired a new position in Krystal Biotech in the 3rd quarter worth approximately $30,000. Salomon & Ludwin LLC acquired a new position in Krystal Biotech in the 3rd quarter worth approximately $33,000. Finally, First Horizon Advisors Inc. grew its position in Krystal Biotech by 212.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after purchasing an additional 166 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

More Krystal Biotech News

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: TD Cowen raised its price target sharply to $306 and maintained a Buy rating — a meaningful analyst upgrade that implies notable upside and likely helped buying interest. TD Cowen Price Target Raise (Benzinga)
• Positive Sentiment: Zacks upgraded KRYS from Hold to Strong Buy, adding another broker endorsement that can boost demand among momentum and quant-driven investors. Zacks Upgrade
• Positive Sentiment: Krystal released a positive interim clinical update for KB407 (Phase 1 CORAL‑1), confirming delivery of wild‑type CFTR to patients’ lungs — a direct biological proof‑of‑concept that materially de‑risks the cystic fibrosis program and is a near‑term clinical catalyst. Business Insider: Positive KB407 Interim Update
• Positive Sentiment: Transcript coverage and management commentary on next steps for KB407 (CORAL‑1) give investors more detail on timing and development plans, helping validate the clinical readout and near‑term milestones. Seeking Alpha: KB407 Transcript
• Neutral Sentiment: Momentum screens and analyst commentary note KRYS’s strong price trend and recent 12‑month outperformance, which can amplify moves but also raises attention to valuation (KRYS has a high P/E relative to later‑stage peers). Zacks: Recent Price Trend

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.